Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (954)

« Back to Publications

African-specific genetic loci determine iron status and risk of severe malaria and bacteremia in African children.

Muriuki JM. et al, (2026), Nat Commun

Recent Advances, Bottlenecks, and Future Directions in Plasmodium falciparum Vaccine Development.

Turan G. et al, (2026), Vaccines (Basel), 14

Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial.

Anywaine Z. et al, (2026), Lancet Infect Dis, 26, 302 - 313

Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].

Mukhopadhyay ES. et al, (2026), Vaccine, 69

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.

Bundi CK. et al, (2026), Front Immunol, 17

Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial.

Kapulu MC. et al, (2026), Nat Med, 32, 178 - 185

Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM.

Mukhopadhyay ES. et al, (2025), Vaccine, 68

Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine.

McDaniel JR. et al, (2025), J Exp Med, 222

Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial.

Dabira ED. et al, (2025), Trials, 26

Core-shell microcapsules compatible with routine injection enable prime/boost immunization against malaria with a single shot.

Guyon R. et al, (2025), Sci Transl Med, 17

Identification of cross-stage, cross-species malaria CD8+ T cell antigens.

Barbosa CRR. et al, (2025), Res Sq

A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine.

Dold C. et al, (2025), Sci Transl Med, 17

A roadmap of priority evidence gaps for the co-implementation of malaria vaccines and perennial malaria chemoprevention.

Grant J. and Perennial Malaria Chemoprevention (PMC) community of practice sub-group on the co-implementation of malaria vaccines and PMC ., (2025), Malar J, 24

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Venkatraman N. et al, (2025), Lancet Microbe, 6

A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease.

Sanderson J. et al, (2025), EBioMedicine, 113

Load More

1
2
3
4
5
6
7
...
»